CAR-Monocytes Clear Heart Scar Tissue and Regenerate Muscle After Heart Attack
Engineered immune cells simultaneously dissolve cardiac fibrosis and rebuild heart muscle in mice, offering a dual-action therapy for heart failure.
Summary
After a heart attack, the heart scars over and loses function — a process that currently has no reversal. Researchers engineered a new type of immune cell called pCAR-Monocytes that do two jobs at once: they seek out and destroy the scar-forming cells (myofibroblasts) using a targeting system borrowed from cancer immunotherapy, and they release a protein called Agrin that stimulates new heart muscle growth. In mouse models of heart attack, these engineered cells reduced scar formation, restored cardiac function, and replenished lost heart muscle. This dual-action approach — clearing fibrosis while rebuilding tissue — is a significant conceptual advance over existing single-target therapies and could eventually apply to fibrotic diseases beyond the heart.
Detailed Summary
Heart attacks kill cardiomyocytes en masse, and the heart responds by replacing lost tissue with fibrous scar — a process that progressively impairs pumping function and leads to heart failure. No current therapy can reverse this fibrotic remodeling while simultaneously regenerating functional muscle, making it one of cardiology's most stubborn unmet needs.
Researchers at Shandong University engineered monocytes — innate immune cells naturally drawn to sites of injury — to express a chimeric antigen receptor (CAR) targeting fibroblast activation protein (FAP), a marker highly expressed on the myofibroblasts responsible for scar formation. These CAR-monocytes were also programmed to secrete Agrin, a protein previously identified as a driver of cardiomyocyte regeneration. The result was a single cellular therapy, termed pCAR-Mos (pleiotropic CAR-monocytes), designed to attack the fibrotic problem from two angles simultaneously.
In mouse myocardial infarction models, pCAR-Mos demonstrated potent phagocytic activity against FAP-expressing myofibroblasts, substantially reducing fibrotic scar burden. Agrin secretion further enhanced myofibroblast clearance while independently promoting cardiomyocyte regeneration. Together, these mechanisms remodeled the cardiac fibrotic microenvironment and led to meaningful restoration of cardiac function compared to controls.
The implications extend beyond cardiology. The authors propose that this platform — immune cells engineered to clear fibrosis and secrete regenerative signals — could be adapted for fibrotic diseases in the liver, lung, and kidney, where similar myofibroblast-driven scarring occurs. The use of monocytes, which naturally home to inflamed tissue, provides a built-in targeting advantage over systemic drug delivery.
Caveats are significant. All data come from mouse models, and translation to humans faces major hurdles including immune rejection of allogeneic cells, manufacturing scalability, and safety profiling. The full study details are not publicly available, as this summary is based on the abstract alone.
Key Findings
- pCAR-Monocytes engineered with FAP-targeting CAR and Agrin secretion reduced cardiac fibrosis in MI mice.
- CAR-mediated phagocytosis of myofibroblasts was amplified by co-secreted Agrin, enhancing scar clearance.
- Agrin secretion independently promoted cardiomyocyte regeneration and functional myocardium replenishment.
- Cardiac function was substantially restored in MI mouse models treated with pCAR-Mos.
- The platform may be adaptable to fibrotic diseases in liver, lung, and kidney beyond the heart.
Methodology
Researchers engineered monocytes to co-express a FAP-targeting chimeric antigen receptor and secrete the regenerative protein Agrin, then tested these pCAR-Mos in mouse myocardial infarction models. Outcomes assessed included fibrotic scar formation, myofibroblast clearance, cardiomyocyte regeneration, and cardiac functional recovery. Study design details beyond the abstract are not available.
Study Limitations
All experiments were conducted in mouse models; human translation faces substantial barriers including immune compatibility, manufacturing scale, and long-term safety. The summary is based on the abstract only, so full methodology, statistical details, and secondary outcomes cannot be evaluated. Durability of cardiac functional recovery and potential off-target phagocytosis of non-myofibroblast FAP-expressing cells were not assessable from available data.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.